GlassScriptPhysician profile
Karen E Green
NPI 1104382803
$3,801.43
in general payments reported to CMS, 2019-2025
36 companies · $896 in 2025
The $896 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $219 · 2023: $1,295 · 2024: $1,391 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.47 |
| Education | $278.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $351.83 | 2023 | Sotyktu |
| Journey Medical Corporation | $346.30 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.90 | 2024 | Dupixent |
| Incyte Corporation | $249.70 | 2023-2024 | Opzelura |
| Amgen INC. | $242.04 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $173.30 | 2023 | Taltz, Olumiant |
| Almirall LLC | $159.98 | 2022-2023 | Seysara |
| Sun Pharmaceutical Industries INC. | $154.76 | 2023-2024 | Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $140.65 | 2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $124.99 | 2024 | Zoryve |
| Ucb, INC. | $122.51 | 2023-2025 | Rystiggo, Bimzelx, Cimzia |
| Pfizer INC. | $122.32 | 2023-2025 | |
| Livanova USA, INC. | $120.43 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $104.90 | 2024 | Valtoco |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $88.87 | 2024-2025 | Austedo Xr, Austedo Xr |
| Genzyme Corporation | $82.08 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $75.00 | 2022 | |
| Emd Serono, INC. | $73.79 | 2024-2025 | |
| Biogen, INC. | $72.14 | 2025 | Tysabri, Vumerity, Leqembi |
| Novartis Pharmaceuticals Corporation | $70.10 | 2024 | |
| Galderma Laboratories, L.P. | $58.13 | 2023 | Aklief, Twyneo, Oracea |
| Octapharma USA, INC. | $54.96 | 2024-2025 | Panzyga |
| Genentech USA, INC. | $53.03 | 2024-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biofrontera INC. | $52.76 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $47.98 | 2025 | Nexplanon |
| Abbvie INC. | $45.04 | 2023-2025 | |
| Leo Pharma INC. | $39.12 | 2025 | |
| Dermavant Sciences, INC. | $36.70 | 2023-2024 | Vtama |
| Ani Pharmaceuticals, INC. | $34.66 | 2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $33.86 | 2025 | Ponvory |
| Sk Life Science, INC. | $33.68 | 2024 | |
| Mentor Worldwide LLC | $23.10 | 2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Catalyst Pharmaceuticals, INC. | $17.85 | 2024 | |
| Medtronic, INC. | $16.89 | 2024 | Percept PC Brainsense |
| Jazz Pharmaceuticals INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.